https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-29 / Rambam Maimonides Med J 2014 Oct;5(4):e0024
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-29 / Rambam Maimonides Med J 2014 Oct;5(4):e00242014-10-29 00:00:002019-02-15 08:39:37Dendritic cell cancer vaccines: from the bench to the bedside
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-18 / Expert Opin Biol Ther 2015 Jan;15(1):79-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-18 / Expert Opin Biol Ther 2015 Jan;15(1):79-942014-10-18 00:00:002019-02-15 08:47:21Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-24062014-10-06 00:00:002021-11-16 07:53:33Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-28 / Cancer Immunol. Immunother. 2015 Jan;64(1):51-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-28 / Cancer Immunol. Immunother. 2015 Jan;64(1):51-92014-09-28 00:00:002019-02-15 08:45:30Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-23 / J Transl Med 2014 Sep;12:262
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-23 / J Transl Med 2014 Sep;12:2622014-09-23 00:00:002019-02-15 08:49:57Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-15 / Radiology 2015 Jan;274(1):192-200
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-15 / Radiology 2015 Jan;274(1):192-2002014-09-15 00:00:002019-02-15 08:52:29Antigen-loaded dendritic cell migration: MR imaging in a pancreatic carcinoma model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-12 / PLoS ONE 2014;9(9):e107173
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-12 / PLoS ONE 2014;9(9):e1071732014-09-12 00:00:002019-02-15 08:47:33Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-11 / Front Oncol 2014;4:224
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-11 / Front Oncol 2014;4:2242014-09-11 00:00:002021-11-15 16:55:17Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-18 / Biomed Res Int 2014;2014:214727
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-18 / Biomed Res Int 2014;2014:2147272014-08-18 00:00:002019-02-15 08:45:57Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-14 / PLoS ONE 2014;9(8):e105266
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-14 / PLoS ONE 2014;9(8):e1052662014-08-14 00:00:002019-02-15 08:48:44Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route
